Levetiracetam (Epilepsy)

Spina bifida

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6330
R26045		 Veiby (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2014 Spina bifida throughout pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 5.22 [0.10;264.46] C
excluded (control group) 		0/114   0/593 0 114
ref
S6332
R26063		 Veiby (Levetiracetam) (Controls unexposed, sick), 2014 Spina bifida throughout pregnancy population based cohort retrospective unexposed, sick Adjustment: No 4.74 [0.24;92.40] C 0/114   3/3,773 3 114
ref
S9832
R35245		 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 Spina bifida at least 1st trimester prospective cohort unexposed, sick Adjustment: No 2.34 [0.05;119.47] C 0/63   0/147 0 63
ref
Total 2 studies 3.67 [0.34;39.26] 3 177
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Veiby (Levetiracetam) (Controls unexposed, sick), 2014Veiby, 2014 1 4.74[0.24; 92.40]311464%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Vajda (Levetiracetam) (Controls unexposed, sick), 2013Vajda, 2013 2 2.34[0.05; 119.47]06336%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 3.67[0.34; 39.26]31770.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.67[0.34; 39.26]31770%NAVeiby (Levetiracetam) (Controls unexposed, sick), 2014 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.67[0.34; 39.26]31770%NAVeiby (Levetiracetam) (Controls unexposed, sick), 2014 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 Tags Adjustment   - No  - No 3.67[0.34; 39.26]31770%NAVeiby (Levetiracetam) (Controls unexposed, sick), 2014 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 All studiesAll studies 3.67[0.34; 39.26]31770%NAVeiby (Levetiracetam) (Controls unexposed, sick), 2014 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 6330

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.67[0.34; 39.26]31770%NAVeiby (Levetiracetam) (Controls unexposed, sick), 2014 Vajda (Levetiracetam) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 5.22[0.10; 264.46]-114 -NAVeiby (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2014 10.510.01.0